High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial

BACKGROUND: Glioblastoma multiforme (GBM) is a rare and deadly disease, with a reported average incidence rate of 3.19 cases per 100,000 inhabitants. Fotemustine, a third-generation nitrosourea with an alanine phosphor carrier that facilitates cellular penetration, has been extensively investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinelli, Alfredo, Lamberti, Giuseppe, Cerbone, Luigi, Cordua, Nadia, Buonerba, Carlo, Peluso, Gianfranco, Di Lorenzo, Giuseppe, De Placido, Sabino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076126/
https://www.ncbi.nlm.nih.gov/pubmed/29979390
http://dx.doi.org/10.1097/MD.0000000000011254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076126/
https://www.ncbi.nlm.nih.gov/pubmed/29979390
http://dx.doi.org/10.1097/MD.0000000000011254

Ejemplares similares